COVID-19 Rapid PCR & Antibody Testing Available Now!
Inquire with us about BioFire FDA EUA approved rapid testing and corporate testing options.

Tower Lab




1-hour results with the FDA-approved BioFire® system

Tower Lab Services is pleased to announce on-site, one-hour PCR COVID-19 infection testing using the BioFire® FilmArray® system. The BioFire® Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 is an FDA EUA-authorized highly sensitive PCR test that will accurately determine if you have a current COVID-19 infection from a nasal swab and give you a certified same day, written results.


What is the testing procedure?

A cotton swab is used to collect an adequate amount of mucous from the nostrils and sent to our on-site lab for immediate analysis.


How long will I have to wait for my results?

Results will be available approximately one hour after specimen submission to our CLIA-certified lab and can be printed out for your records. (Can’t stick around for that long? Just leave us your phone number/email!)


How accurate is this test?

The test has an overall 97.1% sensitivity and 99.3% specificity. That is, this test detects 97.1% of those who are actually infected and identifies the correct virus with 99.3% accuracy.


How much does this test cost?

Medicare patients are fully covered and responsible for any copay. We bill most PPO insurance and your maximum out-of-pocket cost is $300. The cash price is $300.


How do I schedule a test?

Easy, just call 310 659-0705 to book your test or contact us through


Why Is Tower offering this service?

To empower our patients with rapid, accurate and no hassle access to their Covid status.


This test has been authorized by FDA under an EUA for use by authorized laboratories.
This test has not been FDA cleared or approved.
This test has been authorized only for the presence of IgM and IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens.
This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.
This product is intended for professional use and not for home use.
Not for the screening of donated blood.

Additional Resources:


FDA - May 29, 2020

Serology Test Evaluation Report for “COVID-19 IgG/IgM Rapid Test Cassette” from Healgen

COVID-19 IgG/IgM Rapid Test Cassette

Fact Sheets For Recipients

Fact Sheets For Healthcare Providers

Services We Offer and Conditions We Treat

Our Locations

Choose your preferred location